-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $70

Benzinga·03/24/2026 14:04:18
Listen to the news
Wedbush analyst Martin Fan initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Neutral rating and announces Price Target of $70.